[ad_1]
Several analysts see the company hitting the $30 billion revenue mark when it reports earnings next week. The company crossed the $20 billion threshold two quarters ago.
[ad_2]
Source link
FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea
An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March...